© 2022 MJH Life Sciences and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Experts Sandra M. Swain, MD, and Zahi Mitri, MD, MS, reflect on HER2-low breast cancer as a subset of disease and discuss novel therapeutic agents that may improve patient outcomes in this setting.
December 9th 2021
Shared insight on the current state of HER2 classification and testing and in breast cancer, with respect to how it may influence future treatment approaches.
Focused discussion on the methods used to identify a patient’s HER2 status and why it is important to investigate in patients with breast cancer.
Experts take a look at clinical data behind novel antibody drug conjugates and consider how they may impact the management of HER2-low breast cancer.
Practical considerations for the sequencing or combination of novel antibody drug conjugates to optimize outcomes for patients with HER2-low breast cancer.